Liver Diseases clinical trials
The registry lists 824 studies for Liver Diseases across more than 10 countries. 152 are recruiting or about to start. 313 of them are mainly about Liver Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 41 narrower conditions too, such as Carcinoma, Hepatocellular: 13,788 studies, 2,859 open.
ClinicalTrials.gov finds 15,196 studies for Liver Diseases. How that becomes 824 here
This page counts the studies the registry files under Liver Diseases, and those it files under no condition that list Liver Diseasesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 15,196Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −12,335Filed under a narrower condition, counted on its own pageCarcinoma, Hepatocellular 3,327 · Hepatitis C 1,607 · Non-alcoholic Fatty Liver Disease 1,490 · Liver Cirrhosis 927 · Hepatitis B 810 · Liver Neoplasms 733 · 35 more
- −326List Liver Diseases as a condition, but the registry did not file them under itMost often written as “Chronic Liver Disease” (72), “Metabolic Dysfunction-associated Steatotic Liver Disease” (42), and “MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease” (18). The registry filed 145 of them under no condition at all, and the others under other conditions only, most often Fibrosis (37) and Diabetes Mellitus, Type 2 (22).
- −1,711Match it another way165 name it in the title, 21 in a keyword, and 1,525 by a synonym or other text the search reads.
- 824The count on this page
Get an email when these change. Save the Liver Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (21) · Gilead Sciences (15) · National Institute of Allergy and Infectious Diseases (NIAID) (10) · Mirum Pharmaceuticals, Inc. (9) · University of Michigan (9) · Institute of Liver and Biliary Sciences, India (9) · Assistance Publique - Hôpitaux de Paris (9) · Assiut University (7)
What is being tested here
Drugs under test in Liver Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Pegozafermin | 2 | 2 | 4 |
| Hepatitis B Virus Antisense Oligonucleotide AHB-137 | 2 | 0 | 2 |
| Apixaban | 2 | 0 | 2 |
| Lenvatinib | 2 | 0 | 2 |
| Maralixibat | 1 | 2 | 5 |
| Acetylcysteine | 1 | 0 | 5 |
| Rifaximin | 1 | 0 | 4 |
| Everolimus | 1 | 1 | 3 |
| Bepirovirsen | 1 | 0 | 2 |
| Bupropion | 1 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 4 open · Immune checkpoint inhibitors 2 open · mTOR inhibitors 1 open · Angiogenesis inhibitors 3 · Antimetabolites 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide · Phase 3 · Vir Biotechnology, Inc.
- Nov 2026A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection · Vir Biotechnology, Inc.
- Nov 2026Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders · IRCCS San Raffaele
- Nov 2026The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD) · Universiti Kebangsaan Malaysia Medical Centre
- Dec 2026Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa · Oslo University Hospital
- Dec 2026Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis · Insel Gruppe AG, University Hospital Bern
- Dec 2026Role of Combined Ultrasound Elastography in Evaluation the Degree of Liver Fibrosis in Children with Cholesteric Liver Disease · Assiut University
- Dec 2026Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction · Southeast University, China
- Dec 2026Copenhagen Comorbidity in HIV Infection Study · Susanne Dam Nielsen, MD, DMSc
- Dec 2026Liver Disease in Urea Cycle Disorders · Baylor College of Medicine
Who these studies take
Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger. 19 (18%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 19 (18%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 14 (14%) | 14 (14%) |
| 18 | 98 (95%) | 98 (95%) |
| 30 | 95 (92%) | 95 (92%) |
| 40 | 96 (93%) | 96 (93%) |
| 50 | 96 (93%) | 96 (93%) |
| 65 | 93 (90%) | 93 (90%) |
| 75 | 83 (81%) | 83 (81%) |
| 85 | 60 (58%) | 60 (58%) |
Across all 824 studies, recruiting or not: 37% stop at 75 or younger and 18% at 65; 16% take children; 1% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Liver Diseases studies take
Of 53 phase 1 interventional studies under Liver Diseases, half reached primary completion within 14 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 14 mo5–21 · 53 studies | 13 mo5–20 · 48 studies | — |
| Phase 1/2 | 49 mo33–85 · 13 studies | — | — |
| Phase 2 | 36 mo18–49 · 41 studies | — | — |
| Phase 3 | 54 mo37–70 · 19 studies | — | — |
| Phase 4 | 40 mo21–57 · 26 studies | — | — |
| Interventional, no phase | 24 mo12–47 · 135 studies | — | 25 mo12–50 · 122 studies |
| Observational | 47 mo22–120 · 117 studies | — | 48 mo29–124 · 103 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting3
- Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine DisordersNov 3, 2026NCT07206875
- In-situ vs Ex-situ Liver PreservationOct 30, 2026NCT07899853
- ENLIGHT Trial: ESG With Fundal Mucosal AblationOct 15, 2026NCT07792226
Results posted1
Newly registered3
- A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult ParticipantsOct 29, 2026NCT07905157
- In-situ vs Ex-situ Liver PreservationOct 28, 2026NCT07899853
- Incidence of Post TIPS/DIPS Heart Failure and the Factors Associated With Post-TIPS/DIPS Heart Failure.Oct 19, 2026NCT07880639
Studies
Recruiting first, then most recently updated. Showing 50 of 824. Browse all 824 → or search them.
- Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell TransplantNot yet recruitingNCT057222101 country
- Natural History of Noncirrhotic Portal HypertensionRecruitingNCT024177401 country
- Evaluation of Patients With Liver DiseaseRecruitingNCT000019711 country
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)RecruitingNCT07288138Phase 21 country
- A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver DiseaseRecruitingNCT05733832Not applicable1 country
- Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)RecruitingNCT068056953 countries
- Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine DisordersRecruitingNCT072068751 country
- In-situ vs Ex-situ Liver PreservationRecruitingNCT07899853Not applicable1 country
- Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research ApproachRecruitingNCT046852001 country
- A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult ParticipantsNot yet recruitingNCT07905157Phase 1
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsRecruitingNCT07654283Phase 26 countries
- A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaRecruitingNCT06600321Phase 13 countries
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHRecruitingNCT06419374Phase 325 countries
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)RecruitingNCT06318169Phase 327 countries
- A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)RecruitingNCT07431112Phase 19 countries
- "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".RecruitingNCT046909721 country
- TheraSphere Japan Pre-Market StudyRecruitingNCT07377487Not applicable1 country
- ENLIGHT Trial: ESG With Fundal Mucosal AblationRecruitingNCT07792226Not applicable1 country
- Incidence of Post TIPS/DIPS Heart Failure and the Factors Associated With Post-TIPS/DIPS Heart Failure.Not yet recruitingNCT078806391 country
- Biomarker-guided Reduction of Immunosuppression in Liver Transplant Recipients (BRITRE)Not yet recruitingNCT07862439Phase 21 country
- Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific RegionRecruitingNCT07370207Phase 27 countries
- Blood Collection Biorepository for Liver Disease ResearchRecruitingNCT030250741 country
- Cardiovascular Risk Assessment and Coronary Calcium Score in Thai MASLD PatientsRecruitingNCT078659361 country
- Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)RecruitingNCT061939281 country
- Safety and Efficacy of Atorvastatin v. Placebo on HCC RiskRecruitingNCT05028829Phase 21 country
- Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)RecruitingNCT07739914Phase 31 country
- Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; RenewalRecruitingNCT05470205Phase 32 countries
- A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentNot yet recruitingNCT07853040Phase 1
- Liver Micro Flow - MRINot yet recruitingNCT076349391 country
- Patients With Cryptogenic HypertransaminasemiaNot yet recruitingNCT078341251 country
- A-TANGO Phase 2 StudyRecruitingNCT06890039Phase 21 country
- Global Utilization And Registry Database for Improved preservAtion of doNor LiversEnrolling by invitationNCT050820771 country
- Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-AcetylcysteineRecruitingNCT07273071Phase 41 country
- Digital Behavioral Therapy to Reduce Diabetes and Liver Disease RiskNot yet recruitingNCT07032311Not applicable1 country
- A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).RecruitingNCT05895136Phase 25 countries
- Study of Resmetirom in Children and Adolescents With MASHRecruitingNCT07763015Phase 21 country
- Observational Pharmaco-Epidemiology Research & AnalysisRecruitingNCT038138621 country
- Liver Function Test Abnormalities in Pediatric Type 1 DiabetesNot yet recruitingNCT07807553
- Assessment of Microorganisms and Host Response In Liver DiseasesEnrolling by invitationNCT062915711 country
- Detecting Liver Fibrosis in Patients At-riskNot yet recruitingNCT077756381 country
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver CirrhosisRecruitingNCT04874428Phase 11 country
- Liver and Coagulation Disorders in Cardiac Transthyretin AmyloidosisRecruitingNCT077661351 country
- Development and Testing of a Patient-facing Educational Tool About Liver Cancer PreventionRecruitingNCT070103151 country
- Development of a FibroScan Liver Examination Using a Single ProbeRecruitingNCT07400289Not applicable2 countries
- Development of a New Method for Liver Stiffness Measurement Using FibroScanRecruitingNCT06519331Not applicable1 country
- North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver HealthEnrolling by invitationNCT077469991 country
- Patients With Hepatocellular Carcinoma (HCC)Not yet recruitingNCT07690683Not applicable1 country
- Primary Sclerosing Cholangitis in ChildrenRecruitingNCT041811382 countries
- Restrictive Fluid Management In Liver Transplantation (REFIL)RecruitingNCT07695363Not applicable1 country
- Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese PhysiciansRecruitingNCT076823631 country